Ultragenyx Pharmaceutical reported $36M in Debt for its fiscal quarter ending in December of 2025.





Debt Change Date
Acadia Pharmaceuticals USD 73.85M 23.06M Jun/2026
Agios Pharmaceuticals USD 31.17M 4.57M Jun/2026
Alnylam Pharmaceuticals USD 2.48B 1.21B Sep/2026
BioCryst Pharmaceuticals USD 828.6M 510K Dec/2024
BioMarin Pharmaceutical USD 4.19B 11.99M Sep/2026
Immunic USD 0 0 Jun/2024
Insmed USD 544.86M 180.93M Sep/2026
Ionis Pharmaceuticals USD 1.77B 141M Sep/2026
Karyopharm Therapeutics USD 299.23M 35.14M Dec/2025
Kyowa Hakko Kirin JPY 28.75B 5.04B Dec/2024
MacroGenics USD 35.09M 1.42M Jun/2026
Moderna USD 1.29B 11M Jun/2026
Neurocrine Biosciences USD 392.3M 9.5M Sep/2026
PTC Therapeutics USD 2.84B 2.15B Sep/2026
Puma Biotechnology USD 89.06M 55.07M Jun/2024
Regeneron Pharmaceuticals USD 2.71B 400K Jun/2026
Sarepta Therapeutics USD 857.36M 188.48M Sep/2026
Ultragenyx Pharmaceutical USD 36M 2.17M Dec/2025
Vertex Pharmaceuticals USD 6.48B 4.5B Sep/2026